Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8

BACKGROUND: Paclitaxel (PTX) is a potent anti-cancer drug commonly used for the treatment of advanced breast cancer (BCA) and melanoma. Toll-like receptor 4 (TLR4) promotes the production of pro-inflammatory cytokines associated with cancer chemoresistance. This study aims to explore the effect of T...

Full description

Saved in:
Bibliographic Details
Published in:BMC Cancer
Main Authors: Sootichote, Rochanawan, Thuwajit, Peti, Singsuksawat, Ekapot, Warnnissorn, Malee, Yenchitsomanus, Pa-thai, Ithimakin, Suthinee, Chantharasamee, Jomjit, Thuwajit, Chanitra
Format: Artigo
Language:Inglês
Published: BioMed Central 2018
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5830047/
https://ncbi.nlm.nih.gov/pubmed/29486738
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4155-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items